SI-BONE Inc. filed for an IPO to raise about $90 million, which will be used to fund the ongoing commercialization of the company's iFuse implant system.

The Santa Clara, Calif.-based medical device company will offer 6,000,000 common shares at a price of between $13 and $15, according to an Oct. 5 regulatory filing. The company will apply to list its shares on the Nasdaq Global Market under the ticker SIBN.

Underwriters will have a 30-day option to purchase up to an additional 900,000 shares. Assuming full exercise of the overallotment option at the top end of the given price range, the company could raise $103.5 million from the flotation. Existing shareholders have expressed interest for up to $32 million in common shares in the IPO.

SI-BONE intends to use proceeds from the share sale primarily to support ongoing commercialization of the iFuse implant system, a minimally invasive surgical option for patients with sacroiliac joint dysfunction, a source of pain in the low back and legs caused by abnormal motion in the sacroiliac joint.

Morgan Stanley & Co. LLC, Merrill Lynch Pierce Fenner & Smith Inc., Canaccord Genuity LLC and JMP Securities LLC serve as underwriters on the transaction.